UK medicines regulation disincentivising investment in research development, finds survey
The Association of the British Pharmaceutical Industry’s survey results accompany 12 recommendations for improving the Medicines and Healthcare Products Regulatory Agency’s effectiveness as a UK medicines regulator.
Of those respondents with an unfavourable view of the Medicines and Healthcare products Regulatory Agency, 84% attribute their view to the capacity and predictability of the regulator
Shutterstock.com
The majority of pharmaceutical manufacturers responding to a survey have said the UK’s medicines regulatory environment has an ‘unfavourable’ impact on their decision to invest in research development.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.